[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM: Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. Mayo Clin Proc; 2009 Sep;84(9):801-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of acinar cell carcinoma, ductal adenocarcinoma, islet cell carcinoma, or pancreas without evidence of neoplasia.
  • RESULTS: FISH abnormalities were observed in 12 (80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1337-42 [9579843.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):752-61 [15696124.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1766-73 [16030115.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):98-105 [16466998.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10 [16614112.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 1;178(1):26-35 [17889705.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):148-56 [18000365.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Pancreatology. 2008;8(2):110-25 [18382097.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):409-16 [10667595.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):856-62 [11054068.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3946-51 [11099324.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275 [12399802.001]
  • [Cites] J Pathol. 2003 Apr;199(4):453-61 [12635136.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1727-33 [18515795.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] World J Surg. 2009 Jan;33(1):104-10 [19011933.001]
  • (PMID = 19720778.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / P50 CA102701-07; United States / NCI NIH HHS / CA / R01 CA097075; United States / NCI NIH HHS / CA / R01 CA97075
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2735430
  •  go-up   go-down


2. Volkan Adsay N: Cystic lesions of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S71-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic lesions of the pancreas.
  • Although cystic tumors of the pancreas are relatively rare, they constitute an increasingly important category.
  • Consensus criteria for the distinction of these from the ordinary precursors of adenocarcinoma, the pancreatic intraepithelial neoplasia, were established.
  • The definition of mucinous cystic neoplasms was refined; ovarian-like stroma has now become almost a requirement for the diagnosis of mucinous cystic neoplasia, and defined as such, the propensity of these tumors to occur in perimenopausal women became even more striking.
  • Greater accessibility of the pancreas afforded by improved invasive as well as noninvasive modalities has also increased the detection of otherwise clinically silent cystic tumors, which has led to the recognition of more innocuous entities such as acinar cell cystadenoma and squamoid cyst of pancreatic ducts.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / pathology
  • [MeSH-minor] Adenoma / pathology. Carcinoma in Situ / pathology. Humans. Pancreatic Ducts / pathology. Precancerous Conditions

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486054.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Yamaguchi T, Shirai Y, Ishihara T, Sudo K, Nakagawa A, Ito H, Miyazaki M, Nomura F, Saisho H: Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy. Cancer; 2005 Dec 15;104(12):2830-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
  • BACKGROUND: The examination of pancreatic juice cytology could hypothetically contribute to the establishment of a definite diagnosis of malignant intraductal papillary mucinous neoplasm of the pancreas (IPMN), but to the authors' knowledge, its significance has not been confirmed to date.
  • METHODS: The study subjects were comprised of 103 patients with IPMN who underwent surgical resection of pancreatic tumors (adenoma in 29 patients, borderline in 17 patients, carcinoma in situ in 25 patients, and invasive carcinoma in 32 patients).
  • RESULTS: The cytologic diagnosis was found to be of nondiagnostic value in only one patient with an IPMN, whereas it was of no diagnostic value in 14 of the patients with pancreatic carcinoma (17.3%), a difference that was statically significant (P < 0.001).
  • The location of the IPMN (either in the pancreas or the pancreatic ducts) was not found to significantly affect the diagnostic value of the test.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Juice / cytology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Endoscopy, Digestive System / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reference Values. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16287152.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB: Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer; 2006 Jun 25;108(3):163-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized cystic neoplasm of the pancreas, histologically classified by the degree of epithelial atypia and by the presence or absence of invasion of the cyst wall.
  • These cytologic features were subsequently correlated with the histologic diagnosis.
  • Necrosis distinguished IPMN with carcinoma from IPMN-adenomas and IPMN with moderate dysplasia (P < .00001), and was more often observed with invasion than IPMN-carcinoma in situ (P < .05).
  • Pale nuclei with parachromatin clearing was found to be a nuclear feature that was suspicious for at least carcinoma in situ (P < .001).
  • In addition, significant background inflammation (neutrophils and histiocytes) was found to be more characteristic of IPMN with at least carcinoma in situ (P = .002).
  • The presence of tight epithelial cell clusters is consistent with a neoplasm of at least moderate dysplasia, and abundant background inflammation and parachromatin clearing correlated with the presence of at least carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Mucins / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550572.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


5. Grützmann R, Niedergethmann M, Pilarsky C, Klöppel G, Saeger HD: Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist; 2010;15(12):1294-309
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.
  • Pancreatic intraductal papillary mucinous neoplasms (IPMNs) rank among the most common cystic tumors of the pancreas.
  • For a long time they were misdiagnosed as mucinous cystadenocarcinoma, ductal adenocarcinoma in situ, or chronic pancreatitis.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2004 Oct;29(3):212-7 [15367887.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Dig Surg. 2008;25(1):46-51 [18292661.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1127-32 [18299945.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):474-81 [17680299.001]
  • [Cites] Pancreatology. 2008;8(3):277-84 [18497541.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):802-7 [18716113.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2737-41 [18843017.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3187-92 [18766406.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):961-5 [10763945.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):543-7 [12297771.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):234-42 [18040749.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3193-8 [18784959.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1499-507 [18820670.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2 Suppl):S203-9 [19179158.001]
  • [Cites] Pancreas. 2009 Mar;38(2):131-6 [18981954.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Pathologe. 2005 Feb;26(1):22-30 [15624092.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4681-8 [16000561.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1034-42 [15832194.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1650-7 [16311856.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):955-60 [16788757.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):112-6 [16639605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 [16858538.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Pancreatology. 2006;6(6):626-34 [17135772.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] JOP. 2007;8(2):206-13 [17356245.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Apr;5(4):489-95 [17350894.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):440-7 [19247032.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2009;23(1):35-48 [19258185.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):1992-2003 [19225151.001]
  • [Cites] Pancreatology. 2009;9(1-2):34-44 [19077453.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2175-81 [19491823.001]
  • [Cites] Radiology. 2009 Oct;253(1):106-15 [19703865.001]
  • [Cites] Pancreatology. 2009;9(5):631-8 [19657218.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):531-40 [19818780.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):477-82 [20142730.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Pancreas. 2010 Apr;39(3):308-14 [19924021.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Langenbecks Arch Surg. 2003 Dec;388(6):392-400 [12910422.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • (PMID = 21147870.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227924
  •  go-up   go-down


6. Hong SM, Kelly D, Griffith M, Omura N, Li A, Li CP, Hruban RH, Goggins M: Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol; 2008 Dec;21(12):1499-507
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.
  • Ductal adenocarcinoma of the pancreas is the fourth leading cause of cancer death and is usually diagnosed late.
  • Intraductal papillary mucinous neoplasms are an increasingly recognized precursor to invasive ductal adenocarcinoma of the pancreas.
  • Normal pancreas was also obtained from 27 patients with intraductal papillary mucinous neoplasms or pancreatic adenocarcinomas and 10 patients with well-differentiated pancreatic endocrine neoplasms.
  • Carcinomas (intraductal papillary mucinous neoplasms with carcinoma in situ or their associated infiltrating adenocarcinoma) had significantly more methylated genes (71+/-19%) than low-grade (low and moderate dysplasia) intraductal papillary mucinous neoplasms (44+/-26%, P<0.0001).
  • The detection of aberrant methylation in pancreatic cystic lesions could facilitate the diagnosis of intraductal papillary mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):548-65 [16472607.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):365-72 [12105864.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5021-30 [12902985.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):987-93; discussion 993-5 [17481526.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6019-25 [17947463.001]
  • [Cites] Virchows Arch. 2007 Nov;451(5):863-9 [17899180.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):243-9 [18027059.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):850-8 [15592528.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):573-83 [15701843.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • (PMID = 18820670.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-140011; United States / NCI NIH HHS / CA / CA062924-149002; United States / NCI NIH HHS / CA / CA062924-150011; United States / NCI NIH HHS / CA / P50 CA062924-149002; United States / NCI NIH HHS / CA / P50 CA062924-159002; United States / NCI NIH HHS / CA / P50 CA062924-150011; United States / NCI NIH HHS / CA / CA062924-159002; United States / NCI NIH HHS / CA / CA062924-140011
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  • [Other-IDs] NLM/ NIHMS105558; NLM/ PMC2678809
  •  go-up   go-down


7. Kim YN, Park SY, Kim YK, Moon WS: Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ. J Korean Med Sci; 2010 Dec;25(12):1814-7
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ.
  • Pylorus-preserving pancreaticoduodenectomy was performed and diagnosis of XGP combined with intraductal papillary mucinous carcinoma in situ was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Granuloma / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis. Xanthomatosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2004 Mar;28(3):254-7 [14961199.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jan;47(1):36-8 [15471123.001]
  • [Cites] Med Sci Monit. 2008 Nov;14(11):CS130-3 [18971878.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):704-7 [16120922.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):240-2 [18392724.001]
  • [Cites] Urology. 1994 Mar;43(3):295-9 [8134982.001]
  • (PMID = 21165301.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2995240
  • [Keywords] NOTNLM ; Cystic Tumor / Pancreas / Xanthogranulomatous Inflammation
  •  go-up   go-down


8. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


9. Carter RR, Woodall CE 3rd, McNally ME, Talboy GE, Lankachandra KM, Van Way CW 3rd: Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors. Am Surg; 2008 Apr;74(4):338-40
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for mixed ductal-endocrine carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors.
  • This report is a case of a 58-year-old woman with a mixed ductal-endocrine carcinoma of the pancreas and a synchronous carcinoma-in-situ of the common bile duct.
  • Biopsies from this lesion showed adenocarcinoma.
  • Subsequently, pancreatoduodenectomy was performed for the diagnosis of peri-ampullary carcinoma.
  • Gross examination revealed a 2-cm irregular, ulcerated lesion obstructing the distal 0.5 cm of the common bile duct within the head of the pancreas.
  • On histopathological examination, it was discovered that this lesion contained two separate neoplasms: papillary carcinoma-in-situ of the intraparenchymal portion of the common bile duct and a mixed ductal-endocrine carcinoma of the pancreas.
  • Mixed ductal-endocrine carcinoma of the pancreas is very rare.
  • Finding it in conjunction with a synchronous, overlying papillary carcinoma carcinoma-in-situ of the common bile duct has not been previously described.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Common Bile Duct Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453301.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


10. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasia of the pancreas: pathology and biology.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


11. Yamaguchi K, Nakamura M, Shirahane K, Kawamoto M, Konomi H, Ohta M, Tanaka M: Pancreatic juice cytology in IPMN of the pancreas. Pancreatology; 2005;5(4-5):416-21; discussion 421
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in IPMN of the pancreas.
  • BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is a disease ranging from adenoma to borderline (with moderate dysplasia) and further to carcinoma (noninvasive and invasive) and surgical strategy is different by the grades of dysplasia.
  • In 4 patients with the 48 IPM adenomas, diagnosis of pancreatic juice cytology was class IV or V.
  • One of the 4 cases was considered to be an overdiagnosis of cytology, but the other 3 cases were considered to be a consequence of accompanying carcinoma in situ (or PanIN-3) (2 patients) or invasive ductal adenocarcinoma (1 patient) apart from IPMN.
  • When the diagnosis of pancreatic juice cytology is malignant in otherwise benign-looking IPMNs, coexistence of pancreatic carcinoma should be suspected.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Cytodiagnosis / methods. Pancreatic Juice / cytology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / classification. Adenoma / diagnosis. Aged. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985766.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Layfield LJ, Jarboe EA: Cytopathology of the pancreas: neoplastic and nonneoplastic entities. Ann Diagn Pathol; 2010 Apr;14(2):140-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of the pancreas: neoplastic and nonneoplastic entities.
  • Interpretation of cytologic material obtained from the pancreas is complex because of the large number of reactive processes and benign and malignant neoplasms arising within the pancreas.
  • Whereas separation of neuroendocrine, acinar, and ductal neoplasms is usually straightforward, the greatest diagnostic challenge in pancreatic fine-needle aspiration is the separation of atypical epithelium secondary to chronic pancreatitis from well-differentiated ductal adenocarcinoma.
  • Recently, a number of in situ lesions have been identified, complicating the cytologic diagnosis of pancreatic neoplasia.
  • [MeSH-major] Pancreas / pathology. Pancreatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20227021.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


13. Lisovsky M, Dresser K, Woda B, Mino-Kenudson M: Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Hum Pathol; 2010 Jun;41(6):902-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias.
  • Pancreatic intraepithelial neoplasia is a precursor to ductal adenocarcinoma of the pancreas that shows gastric differentiation.
  • Pancreatic intraepithelial neoplasia-3 has the highest potential to progress to adenocarcinoma, and its distinction from lower-grade pancreatic intraepithelial neoplasias is important for clinical management.
  • A product of cell polarity gene lethal giant larvae 2 is a marker of gastric foveolar epithelium expressed in a basolateral fashion, which is lost or mislocalized in gastric epithelial dysplasia and adenocarcinoma.
  • In this study, we investigated a role of lethal giant larvae 2 expression in differentiating low-grade pancreatic intraepithelial neoplasias, that is, pancreatic intraepithelial neoplasia-1 and pancreatic intraepithelial neoplasia-2, from pancreatic intraepithelial neoplasia-3 and pancreatic ductal adenocarcinoma.
  • Conversely, all lesions of pancreatic intraepithelial neoplasia-3 and adenocarcinoma showed loss of lethal giant larvae 2 staining and/or its cytoplasmic localization.
  • Loss or abnormal lethal giant larvae 2 expression is seen in pancreatic intraepithelial neoplasia-3 and adenocarcinoma and might be useful in separating them from lower-grade pancreatic intraepithelial neoplasias.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Cytoskeletal Proteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Cell Polarity. Diagnosis, Differential. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Pancreas / metabolism. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20233622.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


14. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • 18-FDG PET as imaging procedure based on the increased glucose uptake by tumor cells has been suggested for diagnosis and staging of pancreatic cancer.
  • The validation of the diagnosis was made by a surgical procedure (n = 44), a percutaneous biopsy (n = 2), main duct cytology (n = 1), or follow-up (n = 17).
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • Positive criteria of increased uptake on 18-FDG PET was absent in 13 of 13 adenomas and 7 of 8 borderline IPMNs, but was present in 4 of 5 carcinoma in situ (80%) and in 20 of 21 invasive cancers (95%).
  • Conventional imaging technique was strongly suggestive of malignancy in 2 of 5 carcinomas in situ and in 13 of 21 invasive carcinomas (62%).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Hara H, Suda K: Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma. Am J Clin Pathol; 2008 Jan;129(1):115-29
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
  • Invasive ductal adenocarcinoma (IDA) of the pancreas (IDAP) originating from the ductal gland has a poor prognosis.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Hyperplasia / pathology. Mucins / metabolism. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089497.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


16. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery; 2006 Sep;140(3):448-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
  • BACKGROUND: Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings.
  • RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Ovary / cytology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2007 Apr;141(4):545-6 [17383536.001]
  • (PMID = 16934608.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • We report an unusual case of cancer recurrence in an 86-year-old woman who had undergone a pancreaticoduodenectomy for a large IPMN in the head of the pancreas.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Katabi N, Klimstra DS: Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin Pathol; 2008 Dec;61(12):1303-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach.
  • In addition, IPMNs sometimes can be confused with other primary cystic lesions of the pancreas.
  • As a result, the correct diagnosis of IPMN can be challenging.
  • This review addresses the clinical and pathological features of IPMNs, emphasising their diagnostic criteria, differential diagnosis and biological behaviour.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma in Situ / diagnosis. Diagnosis, Differential. Humans. Neoplasm Invasiveness. Pancreatectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703569.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 73
  •  go-up   go-down


19. Krishnasamy R, Agarwal S, Singh S, Puri S, Sakhuja P, Agarwal AK: Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia: report of a case. Hepatobiliary Pancreat Dis Int; 2007 Oct;6(5):553-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia: report of a case.
  • BACKGROUND: The presence of pancreatic ductal intraepithelial neoplasia in patients with chronic pancreatitis is a risk factor for development of pancreatic adenocarcinoma.
  • METHOD: A case of pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia was diagnosed in the setting of chronic pancreatitis.
  • RESULTS: Distal pancreatectomy combined with splenectomy was performed with a diagnosis of pancreatic body carcinoma.
  • Histopathological examination suggested adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia.
  • The tumor was detected in the remaining head of the pancreas, for which a total pancreatectomy was done.
  • CONCLUSIONS: When a patient with pancreatic ductal intraepithelial neoplasia associated with adenocarcinoma of the pancreas in the setting of chronic pancreatitis is at an increased risk of recurrence in the remaining pancreatic parenchyma, total pancreatectomy may be feasible.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Laparoscopy. Laparotomy / methods. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Multiple Primary. Pancreatectomy / methods. Splenectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):106-7 [18234650.001]
  • (PMID = 17897923.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK: MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol; 2006 Mar;186(3):687-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma.
  • OBJECTIVE: The purpose of our study was to evaluate factors predictive of the presence of invasive carcinoma associated with intraductal papillary mucinous neoplasm (IPMN) of the pancreas on MDCT.
  • MATERIALS AND METHODS: Preoperative MDCT of 36 consecutive patients (23 men, 13 women; mean age, 66.6 years) who had undergone surgical resection and had a pathologic diagnosis of IPMN were retrospectively assessed.
  • RESULTS: Pathologic analysis revealed carcinoma in situ in seven patients (19%) and invasive carcinoma in 15 patients (42%) arising from the IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498096.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


21. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH: PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res; 2007 Dec 15;13(24):7380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
  • PURPOSE: The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis.
  • RESULTS: The PAM4-reactive MUC1 epitope was not detected in normal pancreas but was expressed in 87% (48 of 55) of invasive pancreatic adenocarcinomas, including early stage 1 disease: PAM4 labeled 94% (44 of 47) of the earliest PanIN lesions, PanIN-1A and 1B, along with 91% (10 of 11) of PanIN-2, 40% (2 of 5) of PanIN-3, and 86% (31 of 36) of intraductal papillary mucinous neoplasia lesions.
  • A second, unrelated, anti-MUC1 MAb, MA5, showed considerably less sensitivity with early PanIN-1 lesions; only 61% (25 of 41) were positive and the labeling did not differentiate normal pancreas from PanINs.
  • CONCLUSIONS: The results suggest that expression of the PAM4-reactive antigen may represent an early event in the development of invasive pancreatic adenocarcinoma, and is unrelated to the VNTR peptide core epitopes of MUC1.
  • Detection of this biomarker using immunohistology, in vitro immunoassays, and in vivo antibody-based imaging may provide new opportunities for the early detection and improved diagnosis of pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Mucin-1 / metabolism. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Aug 15;14(16):5306; author reply 5306-7 [18698052.001]
  • (PMID = 18094420.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096924; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Mucin-1
  •  go-up   go-down


22. Huo Z, Yang D, Chang XY, Wan JW, Chen J: [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):670-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases].
  • OBJECTIVE: To study the clinicopathologic features and diagnosis of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • It affected patients in older age group (mean age = 59) and was located mainly in the head of pancreas (60%).
  • Features of in-situ or invasive malignancy were present in 15 of the 19 cases (78%).
  • The prognosis after surgical resection however is better than that of conventional pancreatic adenocarcinoma.
  • Early recognition by radiologic examination (including ERCP) and pancreatic cytology would be helpful in early diagnosis.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / analysis. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Cell Cycle Proteins / analysis. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Pancreas / metabolism. Pancreas / pathology. Pancreatectomy. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Prognosis. Receptor, ErbB-2 / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094485.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CDCA5 protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas; 2005 May;30(4):349-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis.
  • Mesothelin mRNA expression was confirmed with in situ hybridization in all 4 resected primary PCa tumors and with RT-PCR in 18 of 20 PCa cell lines, whereas mesothelin protein expression was confirmed with immunohistochemistry in all 60 resected primary PCa tissues by Argani et al.
  • We evaluated mesothelin mRNA expression in pure pancreatic juice (PPJ) obtained from patients with PCa, chronic pancreatitis (CP), and intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Membrane Glycoproteins / genetics. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841046.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / mesothelin
  •  go-up   go-down


24. Dumitrescu D, Popescu CF, Săftoiu A: Intraductal papillary mucinous tumors of the pancreas. Rom J Morphol Embryol; 2010;51(3):447-53
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas.
  • Based on the degree of cytoarchitectural atypia on microscopic examination, IPMTs are classified as benign, borderline, carcinoma in situ and invasive tumors.
  • Imaging examinations are very important to establish the diagnosis.
  • Transabdominal ultrasound, endoscopic ultrasound, computed tomography, magnetic resonance cholangiopancreatography and endoscopic retrograde cholangio-pancreatography have been used for the diagnosis of IPMTs.
  • The correct diagnosis, achieved until recently only with endoscopic retrograde cholangiopancreatography, can be currently obtained with non-invasive imaging modalities, particularly computed tomography and magnetic resonance imaging.
  • Confirmation of the diagnosis requires, however, endoscopic-ultrasound fine-needle aspiration biopsy, followed by cytological or microhistological exams.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Humans. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809019.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  •  go-up   go-down


25. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Uehara H, Nakaizumi A, Iishi H, Takenaka A, Eguchi H, Ohigashi H, Ishikawa O: In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases. Pancreas; 2008 Apr;36(3):236-40
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases.
  • In the present study using an in situ TRAP assay, we investigated the specificity of telomerase activity in pancreatic juice for pancreatic cancer.
  • METHODS: Pancreatic juice were obtained endoscopically at endoscopic retrograde cholangiopancreatography from 10 patients with pancreatic cancer, 4 with intraductal papillary neoplasm, and 3 with normal pancreas.
  • In situ telomerase activity in pancreatic juice samples was examined by in situ TRAP assay and was compared with the results of cytological examination.
  • RESULTS: Of 10 samples from pancreatic cancer, high telomerase activity in situ was detected in 9 and cancer cells in 7.
  • Of 4 samples from intraductal papillary neoplasm, low telomerase activity in situ and mild atypical cells were detected in 2.
  • Telomerase activity in situ was detected in none of 3 samples from normal pancreas.
  • CONCLUSIONS: Detection of in situ telomerase activity in pancreatic juice might help discriminate pancreatic cancer from other pancreatic diseases.
  • [MeSH-major] Pancreatic Diseases / diagnosis. Pancreatic Diseases / enzymology. Pancreatic Juice / enzymology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / enzymology. Telomerase / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / enzymology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / enzymology. Aged. Base Sequence. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / enzymology. Case-Control Studies. DNA Primers / genetics. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362835.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


27. Salvia R, Partelli S, Crippa S, Landoni L, Capelli P, Manfredi R, Bassi C, Pederzoli P: Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. Am J Surg; 2009 Nov;198(5):709-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts.
  • PATIENTS AND METHODS: Our database of patients affected by IPMN was queried to identify patients with a clinicoradiologic or a pathologic diagnosis of multifocal BD-IPMN between January 1990 and December 2006.
  • RESULTS: One hundred thirty-one patients (52 male and 79 female; median age 67 years) had a clinicoradiologic or a histopathologic diagnosis of multifocal BD-IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Female. Humans. Male. Middle Aged. Pancreatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887201.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE: Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg; 2005 Mar;29(3):297-305
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications.
  • Global gene expression profiling holds promise for improved diagnosis and treatment.
  • We have compiled a list of overexpressed genes in pancreatic cancer for which overexpression was confirmed by reverse transcriptase polymerase chain reaction, immunohistochemistry, and/or in situ hybridization following initial identification by global gene expression profiling.
  • The S100 gene family, mesothelin, prostate stem cell antigen, and 14-3-3 sigma, may have important clinical implications in pancreatic cancer diagnosis and treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression / physiology. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1999 Apr;90(4):425-31 [10363581.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):595-600 [12479219.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Feb;16(1):37-52 [12063828.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):441-7 [11950919.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7437-46 [11704875.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):33-7 [9915498.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Electrophoresis. 1999 Oct;20(14):2952-60 [10546833.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 9;281(4):936-44 [11237751.001]
  • [Cites] J Immunother. 2000 Jul-Aug;23(4):473-9 [10916757.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):819-26 [11830538.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3221-8 [11848476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4256-61 [10759549.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):119-24 [8617452.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4587-94 [12085237.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1288-96 [10713670.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):45-50 [11786397.001]
  • [Cites] Eur J Immunol. 2002 Mar;32(3):826-36 [11870627.001]
  • [Cites] Cell Mol Life Sci. 2003 Jun;60(6):1180-99 [12861384.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45201-6 [11574543.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1239-49 [11943709.001]
  • [Cites] World J Surg. 2002 Jul;26(7):783-9 [11948367.001]
  • (PMID = 15696394.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA85822; United States / NCI NIH HHS / CA / R13 CA 1011889
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / S100 Proteins; 0 / mesothelin; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  • [Number-of-references] 39
  •  go-up   go-down


29. Takahashi H, Nakamori S, Nakahira S, Tsujie M, Takahshi Y, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas. Ann Surg Oncol; 2006 Jul;13(7):955-60
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • RESULTS: Of the 20 patients, 13 had benign IPMNs, including adenomas (n = 10) and borderlines (n = 3), and 7 had malignant IPMNs, including carcinomas in situ (n = 4) and minimally invasive IPMNs (n = 3).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788757.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagus / pathology. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Pilot Projects. Sensitivity and Specificity. Stomach / pathology


31. Ikeda S, Maeshiro K, Ryu S, Ogata K, Yasunami Y, Nakayama Y, Hamada Y: Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients. Pancreas; 2009 May;38(4):e102-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients.
  • OBJECTIVES: The diagnosis of small pancreatic cancer remains difficult.
  • Of the 175 patients, 23 (13%) had invasive carcinoma 2 cm or smaller based on histological measurements, 3 intraductal papillotubular adenocarcinoma, and 3 carcinoma in situ (CIS).
  • A definite diagnosis was obtained based on the findings of main duct stenosis or obstruction with marked stricture of the branch ducts (n = 18) and a filling defect in the main duct (n = 2).
  • CONCLUSIONS: Balloon spot pancreatography is an essential tool for the diagnosis of small ductal pancreatic cancer, and it also makes it possible to locate CIS lesions of the branch ducts.
  • [MeSH-major] Catheterization. Cholangiopancreatography, Endoscopic Retrograde / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / diagnosis. Female. Humans. Male. Middle Aged. Pancreatitis / diagnosis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287333.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM, Settmacher U, Hommann M, Richter KK, Daffner W, Täubig H, Manger T, Claussen U, von Eggeling F: Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem; 2007 Apr;53(4):629-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker.
  • We identified proteins by use of 2-dimensional gel electrophoresis, peptide fingerprint mapping, and immunodepletion and used immunohistochemistry for in situ localization of the proteins found.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Heat-Shock Proteins / analysis. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. Proteome / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303689.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


33. Goh BK, Chung YF, Ng DC, Selvarajan S, Soo KC: Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP; 2007;8(3):350-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
  • A total pancreatectomy was performed and the final histology demonstrated a main-duct type intraductal papillary mucinous neoplasm with a focus of high-grade dysplasia compatible with carcinoma-in-situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495366.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Tanaka M: Important clues to the diagnosis of pancreatic cancer. Rocz Akad Med Bialymst; 2005;50:69-72
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important clues to the diagnosis of pancreatic cancer.
  • Widespread awareness of important clues to the diagnosis is particularly important to improve the prognosis.
  • Dilatation of the main pancreatic duct on ultrasonograms and/or CT scans, hyperamylasemia incidentally found during routine blood examinations, and recent onset diabetes mellitus must lead to thorough imaging studies of the pancreas.
  • Of particular interest is the fact that two of the 9 patients had carcinoma in situ that could be diagnosed only by cytology of the pancreatic juice.
  • IPMN may be the only clue to the early diagnosis of pancreatic carcinoma presenting with no clinical symptoms or abnormalities on imaging studies.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358942.001).
  • [Journal-full-title] Roczniki Akademii Medycznej w Białymstoku (1995)
  • [ISO-abbreviation] Rocz. Akad. Med. Bialymst.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


35. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, Fujita Y, Uchiyama K, Yamaue H: Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg; 2009 Apr;144(4):345-9; discussion 349-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
  • PATIENTS: Fifty-four patients with IPMN who underwent surgery; histologic examination showed benign adenomas in 29, carcinoma in situ in 14, and invasive carcinoma in 11 patients.
  • CONCLUSION: Measurement of the CEA level in pancreatic juice should be considered in the diagnosis of IPMC.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380648.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Janot MS, Kersting S, Chromik AM, Tannapfel A, Uhl W: [Amyloidosis of the small intestine following whipple operation is a rare cause of chronic ileus and has to be considered as differential diagnosis]. Zentralbl Chir; 2010 Aug;135(4):345-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Amyloidosis of the small intestine following whipple operation is a rare cause of chronic ileus and has to be considered as differential diagnosis].
  • INTRODUCTION: When patients who underwent a Whipple operation because of a tumour of the pancreas develop symptoms of chronic ileus several months after surgery, the most common cause is a relapse of tumour growth or a peritoneal carcinomatosis.
  • In this paper we report that secondary amyloidosis of the small intestine can produce similar symptoms and has to be evaluated as a rare differential diagnosis in chronic ileus.
  • In two patients surgery was performed due to carcinoma in situ and in one patient due to benign cystadenoma of the pancreas.
  • Surgeons have to keep in mind that amyloidosis is a possible differential diagnosis in addition to relapse of tumour growth and peritoneal carcinomatosis in these patients.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Amyloidosis / diagnosis. Cystadenoma, Mucinous / surgery. Ileus / diagnosis. Intestinal Diseases / diagnosis. Intestine, Small. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Postoperative Complications / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Chronic Disease. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Tissue Adhesions / diagnosis. Tissue Adhesions / pathology. Tissue Adhesions / surgery

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart ˙ New York.
  • (PMID = 20464655.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Wente MN, Schmied BM, Schmidt J, Büchler MW: [Differentiated therapy for intraductal papillary mucinous neoplasms]. Chirurg; 2009 Jan;80(1):7-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMN) of the pancreas are of increasing interest in the field of pancreatic surgery ever since their first description as an individual pancreatic tumor entity in 1982.
  • Invasive IPMN forms (carcinoma in situ and invasive carcinoma) and in particular noninvasive IPMNs (adenoma and borderline tumors) reveal significantly better survival rates than ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / diagnosis. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Prognosis. Radiography, Dual-Energy Scanned Projection. Survival Rate. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):344-7 [10587197.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):966-74; discussion 974-5 [18043098.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):322-33 [18813200.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] Gut. 2008 Nov;57(11):1490-1 [18941002.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):414-6 [17968632.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] J Clin Pathol. 2008 Dec;61(12):1303-13 [18703569.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19082569.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


38. Schmid RM: [Pancreatic cancer]. Praxis (Bern 1994); 2006 Nov 1;95(44):1709-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancer in the pancreas is ductal adenocarcinoma.
  • Patients with tumors in the head of the pancreas may present deep jaundice without pain.
  • Multidetector CT incorporating dual-phase imaging in the arterial and venous phases of enhancement is the preferred imaging modality for the diagnosis and staging of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Gene Expression Regulation, Neoplastic / genetics. Genes, ras / genetics. Humans. Palliative Care. Pancreas / pathology. Pancreatectomy. Prognosis. Smad4 Protein / genetics. Tomography, X-Ray Computed. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111879.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


39. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC: Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn; 2010 Nov;12(6):780-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatobiliary tract strictures result either from malignancies of the biliary tract and pancreas or from nonmalignant etiopathogenesis.
  • The goal of this study was to determine whether KRAS mutations could be identified in residual pancreatobiliary stricture brushings and to compare the performance characteristics of KRAS mutation analysis to cytology and fluorescence in situ hybridization (FISH) for the detection of carcinoma.
  • Residual brushing cytology cell pellets were retrieved from 132 patients with subsequent clinicopathologic follow-up of cholangiocarcinoma (n = 41), pancreatic adenocarcinoma (n = 35), gallbladder cancer (n = 2), and nonmalignant strictures (n = 54).
  • KRAS mutations and polysomic (ie, positive) FISH results were identified in 24 (69%) and 22 (63%) pancreatic adenocarcinoma specimens, respectively, with a combined sensitivity of 86% (30/35).
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Cholangiopancreatography, Endoscopic Retrograde. Cytodiagnosis / methods. DNA Mutational Analysis / methods. In Situ Hybridization, Fluorescence / methods. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jun 25;93(3):229-35 [11391612.001]
  • [Cites] Gut. 2001 Mar;48(3):403-8 [11171833.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1675-81 [15330900.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):629-35 [10100716.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):412-20 [15467712.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1315-20 [16311354.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Diagn Cytopathol. 2007 Apr;35(4):218-24 [17351944.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] J Clin Gastroenterol. 2007 Nov-Dec;41(10):906-10 [18090159.001]
  • [Cites] Liver Int. 2008 Jan;28(1):12-27 [18031477.001]
  • [Cites] World J Gastroenterol. 2008 Feb 21;14(7):1097-101 [18286693.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):353-360 [18075308.001]
  • [Cites] Oncol Res. 2008;17(4):151-7 [18773859.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1270-8 [18995218.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2180-6 [19232347.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):196-203 [19546608.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):519-27 [19636327.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6 [19501586.001]
  • [Cites] Arch Pathol Lab Med. 2009 Oct;133(10):1600-6 [19792050.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):543-52 [19815694.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):583-9 [19815696.001]
  • [Cites] Pancreas. 2009 Nov;38(8):890-5 [19752775.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):387-92 [10705391.001]
  • [Cites] Diagn Cytopathol. 2002 May;26(5):273-7 [11992366.001]
  • (PMID = 20864634.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2963905
  •  go-up   go-down


40. Stelow EB, Adams RB, Moskaluk CA: The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms. Am J Surg Pathol; 2006 Jan;30(1):36-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma is thought to develop through a series of genetic events through its purported precursor lesion, pancreatic intraepithelial neoplasia (PanIN).
  • Little, however, is known regarding the role of possible precursor lesions in the development of other primary neoplasms of the pancreas.
  • All pancreata resected at the University of Virginia from June 1, 1991 to March 1, 2005 for neoplasia not diagnosed as conventional ductal adenocarcinoma were reviewed and classified according to the World Health Organization's classification schema for tumors of the exocrine and endocrine pancreas.
  • Although the high prevalence of PanIN in pancreata concomitantly harboring certain uncommon neoplasms of the pancreas could signify its role as a precursor lesion for those neoplasms, its high prevalence throughout our series may simply be the result of a coincidental, prevalent finding seen in all pancreata, especially with aging.
  • Because of the ubiquitous nature of PanIN, it should not be used histologically to assist in the diagnosis and subclassification of pancreatic neoplasia.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Age Factors. Aged. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prevalence

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330940.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Saif MW: Primary pancreatic lymphomas. JOP; 2006;7(3):262-73
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An accurate cytopathologic diagnosis by fine-needle aspiration (FNA) is imperative because the primary treatment is non-surgical.
  • FNA coupled with flow cytometry analysis appears to be highly accurate in the diagnosis of primary pancreatic lymphomas.
  • Fluorescence in-situ hybridisation technique has been established its role in the diagnosis of lymphoid malignancies, including primary pancreatic lymphomas.
  • Primary pancreatic lymphomas has a much better prognosis than adenocarcinoma of the pancreas.
  • [MeSH-major] Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685107.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 40
  •  go-up   go-down


42. Buchholz M, Braun M, Heidenblut A, Kestler HA, Klöppel G, Schmiegel W, Hahn SA, Lüttges J, Gress TM: Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene; 2005 Oct 6;24(44):6626-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours.
  • Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.
  • [MeSH-major] Carcinoma in Situ / genetics. Pancreatic Neoplasms / genetics. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103885.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger
  •  go-up   go-down


43. Pilleul F, Rochette A, Partensky C, Scoazec JY, Bernard P, Valette PJ: Preoperative evaluation of intraductal papillary mucinous tumors performed by pancreatic magnetic resonance imaging and correlated with surgical and histopathologic findings. J Magn Reson Imaging; 2005 Mar;21(3):237-44
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At histologic analysis, three cases were classified as benign, three as borderline tumors, and 18 as carcinomas (eight in situ, 10 invasive).
  • Excellent agreement was found between the interpreters (0.90) in the evaluation of ductal involvement, good in the evaluation of lesion location (0.80) and in the diagnosis of malignant transformation (0.74).
  • The correlation between MRI and histopathologic results was excellent in the evaluation of ductal involvement (0.90, sensitivity = 100%, specificity = 94%) and moderate in the evaluation of lesion location (0.57, sensitivity = 87%, specificity = 56%) and in the diagnosis of malignant transformation (0.60, sensitivity = 83%, specificity = 83%).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Magnetic Resonance Imaging / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15723374.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kim JC, Kim MH, Lee TY, Kim JY, Han JH, Park SJ, Lee SS, Seo DW, Jang SJ, Lee SK: [Clinicopathologic review of 41 cases of pancreatic mucinous cystic neoplasms]. Korean J Gastroenterol; 2008 Jan;51(1):34-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were to define the natural history of resected mucinous cystic neoplasms of the pancreas and to identify the findings which suggest malignancy.
  • Thirty three patients (80.6%) had adenoma, 1 (2.4%) borderline malignancy, 1 (2.4%) carcinoma in situ, and 6 (14.6%) invasive mucinous cystadenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2008 Jan;51(1):60-3 [18349566.001]
  • (PMID = 18349560.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


45. Okabayashi T, Kobayashi M, Nishimori I, Sugimoto T, Namikawa T, Okamoto K, Okamoto N, Kosaki T, Onishi S, Araki K: Clinicopathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol; 2006 Feb;21(2):462-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to identify preoperative features that may be predictors of malignant IPMN, and to define the medical management of IPMN of the pancreas.
  • METHODS: A total of 23 patients who underwent surgical resection for IPMN of the pancreas at Kochi Medical School between 1982 and 2004 were examined.
  • RESULTS: Among the 23 patients, 12 had IPMN adenoma, three had borderline IPMN, four had IPMN with carcinoma in situ, and four had IPMN with invasive carcinoma.
  • These results suggest that the following IPMN of the pancreas should be resected: (i) IPMN of the pancreas situated in the main duct;.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Pancreatectomy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509876.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


46. Haugk B: Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology; 2010 Oct;57(4):503-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic cancer is a heterogeneous group in which pancreatic ductal adenocarcinoma (PDAC) is the most common.
  • Great advances in the understanding of pancreatic carcinogenesis have opened avenues for diagnosis and chemoprevention.
  • However, access to the pancreas is limited, molecular tests are at the early stages and too little is known about the natural history of early PanINs to justify resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Early Detection of Cancer. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20875068.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


47. Nanashima A, Kinoshita N, Nakanuma Y, Zen Y, Sumida Y, Abo T, Hidaka S, Takeshita H, Yasutake T, Hayashi T, Nagayasu T: Clinicopathological features of "intraductal papillary neoplasm of the bile duct" and patient outcome after surgical resection. Hepatogastroenterology; 2008 Jul-Aug;55(85):1167-73
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Intraductal papillary neoplasm of the bile duct (IPNB) represents a biliary papillary tumor mainly growing in the bile duct lumen resembling intraductal papillary mucin-producing neoplasm of the pancreas.
  • Tumor markers were not valuable for diagnosis.
  • Five cases were well-differentiated adenocarcinoma and 1 had poorly differentiated adenocarcinoma.
  • In-situ spread of carcinoma was seen along biliary mucosa in 3 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795651.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement